Prices delayed by at least 15 minutes | Print
ADDEX N (ADXN)
This share can be held in a Dealing accountISALifetime ISAJISASIPP
Company profile
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.
Address
12, chemin des Aulx
1228 Plan-les-Ouates
Geneva
CHE
Telephone
+41 228841511
Forecast key dates
| Name | Key Date |
|---|
Previous key dates
| Name | Key Date |
|---|---|
| Addex Therapeutics Ltd Second Quarter Earnings Conference Call for 2023 | 2023-08-18T10:00:00 |
| Addex Therapeutics Ltd Second Quarter Earnings Results for 2023 | 2023-08-18T00:00:00 |
| Addex Therapeutics Ltd Annual General Meeting for 2022 | 2023-05-09T11:00:00 |
| Addex Therapeutics Ltd First Quarter Earnings Results for 2023 | 2023-05-05T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.